PCORI is not quite a household name, but if Dr. Anne Beal has her way, it will be soon. The acronym stands for Patient Centered Outcomes Research Institute—a group of doctors, researchers, statisticians and patient advocates who will commission evidence-based research for the health care system. The goal, according to Beal, is to provide easy-to-understand information to patients so they can make the most informed health care decisions.
The quasi-governmental institute is partially funded through a $1-per-enrollee fee on certain insurers; the fee increases to $2 per person in 2013. It is enforced by the I.R.S. The new organization and its financing drew an attack this week from the Senate Republican Policy Committee. According to the committee's blog, this fee "represents a complete turnaround from an Administration that campaigned against taxing health benefits."
But Beal defends the levy, saying it would "help people decide what's best for them in getting their desired health outcome." She said more progressive insurers see this fee as an investment into PCORI's mission.
Read the full story and Q&A at: http://www.kaiserhealthnews.org/Stories/2012/January/09/PCORI-Q-and-A.aspx
Source: Kaiser Health News
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More
Gestational Diabetes Is a Key Population Health Opportunity
December 7th 2023Diagnosing and treating gestational diabetes can have long-term positive effects on the health of the mother and the baby, warranting a distinct focus on the condition, according to an Institute for Value-Based Medicine® event held in Cleveland, Ohio.
Read More
Refining Precision Prevention for Benign Breast Disease
December 7th 2023Many questions remain surrounding accurately classifying the risk of developing invasive breast cancer associated with the benign breast disease diagnoses of nonproliferative lesions and proliferative changes without atypia.
Read More
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More